Providence & Swedish Hospital Systems CEO Rod Hochman. Get this, this huge hospital group is no longer called a hospital group or medical group, but " (CEO of) Providence Digital Innovation Group"

https://www.providence-dig.org/

Totally not a sign of assimilating man to quantum AI driven hive machine.

https://www.weforum.org/agenda/2022/04/ceos-explain-how-to-respond-to-the-biggest-challenges-in-healthcare/

https://blog.rodhochmanmd.org/introducing-tegria-our-new-services-and-solutions-company

https://diversey.gcs-web.com/board-member/rod-hochman

Here is an email sent to system staff and physicians:

"A new operating model

Simplifying our leadership structure to support caregivers and patients

Dear core leader,

As part of our vision of Health for a Better World, the Providence family of organizations has been working to create a more sustainable model of health care by 2025, one that makes safe, high-quality care accessible and affordable for everyone. We began this journey before the pandemic, but it has become even more imperative today as health systems across the country face a new reality.

External forces – including the national shortage of health care personnel, inflation and global supply chain disruptions – have strained patient care operations throughout the U.S. while also driving up the cost of care. Meanwhile, reimbursement from insurers has not kept pace, resulting in unprecedented net operating losses for health systems nationally.

Having served the Western U.S. for more than 165 years, Providence has lived through other economic downturns, past pandemics and periods of political and social unrest. The Mission endured because our founding sisters responded to the times with faith, foresight and flexibility, making hard choices when resources were constrained and not letting “past practice constrict the vision of what is best for the future.”

A leaner executive team

Now, it is up to us to write the next chapter. As resources become increasingly scarce, supporting caregivers and meeting the needs of patients remain our top priority. Recently, we completed a thoughtful ethical discernment and established guiding principles to help the system and our ministries and affiliates navigate the times consistent with our values."

pt 1

>>16768169

The process led to a more streamlined operating model that will free-up resources for the frontlines, make our ministries and affiliates nimble enough to adapt to a fast-changing world, and empower local decision-making to meet the unique needs of each of their communities.

A key aspect of this change is grouping our existing seven regions into three new divisions. The groupings are based on similar strategies, demographics, as well as revenue size, and will reduce the number of executives in our organization by moving our system from seven executive leadership teams to three.

Erik Wexler, who has been serving as president of operations and strategy for our southern regions, will take on a new role as chief operating officer for Providence. He will oversee the following three new divisions, with the support of these leaders:

· South (Southern and Northern California) – Kevin Manemann will serve as the south division chief executive. He’ll maintain his responsibilities for Southern California operations, with Laureen Driscoll continuing as the regional chief executive for Northern California reporting to Kevin.

· Central (Oregon, Eastern Washington/Montana, Texas/New Mexico) – Joel Gilbertson will serve as the central division chief executive. He’ll maintain his responsibilities for Eastern Washington/Montana operations. William Olson will serve as the regional chief executive for Oregon, and Walt Cathey will continue as the regional chief executive for Texas/New Mexico. Both will report to Joel.

· North (Puget Sound and Alaska) – Guy Hudson, M.D., will serve as the north division chief executive. He’ll retain his role as president and CEO of Swedish and will continue to maintain his responsibilities for Puget Sound Region. Preston Simmons will serve as regional chief executive for Alaska reporting to Guy.

With the above leaders identified, the next step is to begin the process of interviewing and selecting other members of the divisional leadership teams. Meanwhile, our shared services will adapt their structure to support the leaner operating model.

Another key change is that leadership for our Physician Enterprise, Ambulatory Care Network and Clinical Institutes is being consolidated under one executive leadership team, led by David Kim, M.D., who brings a strong clinical foundation and track record for thinking innovatively to drive quality, value and performance.

pt 2

>>16768172

Thank you

As the new divisional leadership teams are selected, please know we are absolutely committed to going through this process with respect and compassion for each person involved. We will also keep the focus on retention and recruitment for essential roles, especially on the frontlines. Each of you continue to give your heart and soul to the Mission, and we remain deeply grateful for your incredible service.

Recognizing this is a time of heightened anxiety for many as we face severe staffing shortages and capacity issues, I want to remind everyone of the mental health and well-being resources available through Providence. I encourage you to take advantage of them.

While the next six months will be challenging, the steps we are taking will allow us to hit the ground running in the New Year, putting us well on our way to Destination Health 2025. Together, we will continue supporting caregivers and serving patients in local communities throughout these difficult times while shaping the future of health care nationally. Thank you.

Rod Hochman, M.D.

President and CEO

3 of 3

https://mobile.twitter.com/justin_hart/status/1549491387875205120

Justin Hart

@justin_hart

They're saying the quiet part out loud now. Here's Jane Goodall doing her best impression of Thanos yet!

https://mobile.twitter.com/Spiro_Ghost/status/1549548392396857347?cxt=HHwWhoC9sbKDjYErAAAA

Covid-1984

@Spiro_Ghost

This Is A World Economic Forum Video From 7 Years Ago…

Titled 'RNA Therapeutics & DNA Editing'

Described Is An Experiment That Genetically Targeted Black Mice To Turn Them Into White Mice…

Imagine The Possibilities… I Sure Hope That Tech Doesn't Fall Into The Wrong Hands

Why You'll Need to Get COVID-19 Boosters Again and Again

https://time.com/6198402/covid-19-boosters/

BY AKIKO IWASAKI AND ALBERT KO JULY 19, 2022 7:00 AM EDT

Iwasaki is the Sterling Professor of Immunobiology and Professor of Dermatology and of Molecular, Cellular, and Developmental Biology and of Epidemiology at Yale University School of Medicine

Ko is the Raj and Indra Nooyi Professor of Public Health and Professor of Epidemiology (Microbial Diseases) and of Medicine (Infectious Diseases) at Yale University School of Medicine

Several highly effective vaccines were developed at an unprecedented speed to combat the COVID-19 pandemic. During the phase 3 clinical trials, mRNA vaccines had vaccine efficacy of 94–95% in preventing symptomatic infections. After the rollout, real-world evidence showed that the mRNA vaccines provided ~90% effectiveness against infection. Then came the variants. The wave after wave of new variants, with ever-increasing transmissibility and capacity to escape existing immunity, challenge the ability of vaccines to prevent infection and transmission. The effectiveness of a primary series of mRNA vaccines (two doses) to prevent hospitalization and death is also being chipped away by these highly immune-evasive variants. Vaccine-mediated protection became shorter-lived, especially with the emergence of Omicron variants. People look at these data and wonder, what is the point of getting the vaccines if they will not prevent symptomatic infections, and the protection does not last? Well, to expect robust protection from just the primary series of any vaccines is unreasonable—and was always likely to be—but somehow society has placed too high a bar on what is considered an acceptable number of doses for COVID-19 vaccines. Instead, we need to understand that we’re going to be getting boosters in the foreseeable future, and to appreciate their benefits.

pt 1

>>16768276

Vaccines against other infectious diseases are given in multiple doses. Many of our childhood vaccines require multiple doses—5 doses for (diphtheria/tetanus/pertussis), 4 doses (Haemophilus influenza type b, pneumococcal conjugate, inactivated poliovirus), or 3 doses (hepatitis B) are all commonly given before the age of 18 years. These doses are required and not considered optional to achieve immunity. In adulthood, many of these vaccines need periodic booster doses to maintain immunity. The influenza virus requires annual vaccination doses for all ages. Yet, people don’t complain about having to get their 60th dose of the influenza vaccine. We should think of COVID-19 vaccines the same way.

Why do we need booster doses? The primary series of vaccines kick-starts the immune response by engaging lymphocytes, white blood cells that detect specific features of the pathogen to expand in numbers and become instructed to eliminate the pathogen. Most of these cells disappear over time, except for a small subset of cells that are kept by the body for future use. These “memory cells” are responsible for long-lasting immunity against a given pathogen. What boosters do is stimulate these memory lymphocytes to quickly expand in numbers and to produce even more effective defenders. The booster also selects for B cells that can secrete antibodies that are even better at binding and blocking virus infection and spread.

The primary series can be thought of as the high school for lymphocytes, where naïve cells receive basic instructions to learn about the pathogen. Boosters are like a college where lymphocytes are further educated to become more skilled and mature, to fight off future infections. Periodically, these college graduates need refreshers by more booster doses given later in life. This is the case for all vaccines. Booster doses provide the immune system the education it needs to prevent severe diseases from infections.

pt 2

>>16768280

COVID-19 vaccines also need booster doses for the same reasons. We need to educate, maintain, and improve T and B cell responses to prevent severe disease. Boosters provide significant benefits to people who received the primary series in preventing hospitalization and death. In the U.S. in April 2022, people older than 50 years of age who received no vaccine, primary series only (no booster dose), or one booster dose had 38 x, 6 x, or a 4 x higher risk, respectively, of dying from COVID-19 compared to those with two or more booster doses. During the Omicron-predominant period, the booster dose provided protection from hospitalization even in previously infected people, whether older (>65 years of age) or younger (<65 years of age). Among children and adolescents, a primary series (two doses) of vaccination was less effective in preventing COVID-19-associated emergency department and urgent care encounters during the Omicron wave compared to the Delta period. Immunity also decreases with time since primary vaccination. No significant protection was detected more than five months after a 2nd vaccine dose among adolescents aged 16–17 years. However, a third booster dose restored vaccine effectiveness to 81% in this age group. There is thus a clear benefit of a booster dose across a broad range of age groups studied to date.

Can booster vaccination be improved in the future? Absolutely. We need improved boosters that can provide more durable protection, are effective against variants we encounter moving forward, and do a better job of preventing infection and blocking transmission. For example, booster-induced immune protection wanes within 4-6 months during the current Omicron period. We need vaccine strategies that provide more durable protection. Boosters are now being developed to match the circulating Omicron variant BA.5, which should provide better protection than boosters based on the original strain. However, because of the rapidly mutating nature of SARS-CoV-2, going forward, we will need boosters that can provide coverage against not just the existing but future variants of concern.

Boosters that work against a wide range of SARS-CoV-2 variants, now or in the future, as well as against other coronaviruses that may cause future pandemics need to be pursued. Coronaviruses have made the jump from animals to humans multiple times in history which resulted in pandemics. Vaccines that can broadly protect against a wide range of coronaviruses will also prevent future pandemics. In addition, future boosters should be given as nasal spray vaccines to provide local mucosal immune protection, capable of reducing infection and transmission at the portal of entry for the virus, and reducing long COVID risk. Ultimately, we need booster strategies that can be more easily implemented worldwide and have higher acceptance and uptake rates to provide much-needed immune protection for everyone. An over-the-counter nasal spray booster can bring us closer to that goal.

Researchers and industry are furiously working on developing next-generation vaccines as they did with our current vaccines, which have saved more than 14 million lives during the pandemic. But for now, take the booster doses you are eligible to keep your immune system educated and up to date so it has the best chance of protecting you from COVID-19 in the upcoming winter season and so we can prevent the enormous loss of life we experienced last winter with more than 300,000 people dying in the U.S. from a disease that can be prevented by current boosters.

3 of 3